Cargando…
Is the Evaluation of Quality of Life in NSCLC Trials Important? Are the Results to be Trusted?
The majority of patients with non-small cell lung cancer present at the time of diagnosis with stage IV metastatic disease and they experience 2 or more disease-related symptoms. These symptoms may have a negative impact on their health-related quality of life (HR QOL). Data has shown many of these...
Autor principal: | Hirsh, Vera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4080131/ https://www.ncbi.nlm.nih.gov/pubmed/25072024 http://dx.doi.org/10.3389/fonc.2014.00173 |
Ejemplares similares
-
Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014) -
Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014) -
Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients
por: Li, Wen, et al.
Publicado: (2022) -
Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014) -
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC
por: Zer, Alona, et al.
Publicado: (2014)